Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Tax loss bouncing into January could be pretty profitable.
Many tax loss bounce possibilities out there. Buying from the tax loss sellers that are overdoing it as they rush to book the loss.
Biotechs are getting hit because they ran earlier in the year and are off their lows.
Biotechs usually...usually... do well in the first quarter of a year.
The iBox is the Intro.
NIH study traces molecular link from gene to late-onset retinal degeneration
Scientists have discovered that gene therapy and the diabetes drug metformin may be potential treatments for late-onset retinal degeneration (L-ORD), a rare, blinding eye disease. Researchers from the National Eye Institute (NEI), part of the National Institutes of Health generated a “disease-in-a-dish” model to study the disease. The findings are published in Communications Biology.
“This new model of a rare eye disease is a terrific example of translational research, where collaboration among clinical and laboratory researchers advances knowledge not by small steps, but by leaps and bounds,” said Michael F. Chiang, M.D., director of the NEI, part of the National Institutes of Health.
L-ORD is a rare, dominantly inherited disorder, meaning that it can occur when there is an abnormal gene from one parent. L-ORD is caused by a mutation in the gene that encodes the protein CTRP5. People with the disorder develop abnormal blood vessel growth and deposits of apolipoprotein E, which is involved in fat metabolism within the retina. Symptoms, including difficulty seeing in the dark and loss of central vision, usually appear around age 50 to 60. As L-ORD progresses, cells in the retinal pigment epithelium (RPE), a layer of tissue that nourishes the retina’s light-sensing photoreceptors, shrink and die. Loss of RPE leads to the loss of photoreceptors and in turn, to loss of vision.
The investigators were led by Kapil Bharti, Ph.D., who directs the NEI Ocular and Stem Cell Translational Research Section, and Kiyoharu (Josh) Miyagishima, Ph.D. and Ruchi Sharma, Ph.D., staff scientists in the section and leading authors of the study. They developed a laboratory model that uses induced pluripotent stem cells developed from skin (fibroblasts) to make RPE. They generated RPE from two siblings with L-ORD and, for comparison, RPE from two of the patients’ unaffected siblings who lacked the disease-causing mutation.
The patient-derived RPE shared key characteristics of the disorder in humans, including deposits of apolipoprotein E near the tissue, and abnormal secretions of vascular endothelial growth factor, a protein that stimulates blood vessel growth. The RPE cells also were dysmorphic, or deformed. By contrast, RPE from the unaffected siblings appeared normal. The researchers also found that the patient-derived RPE secreted far less of the mutant and the non-mutant CTRP5 protein compared with the models made from the unaffected siblings.
Using a computer modeling technique, they showed that mutant CTRP5 was less likely to bind with cell receptors that help fine-tune fat metabolic regulation. Less receptor binding in turn leads to chronic activation of AMP-activated protein kinase (AMPK), a key regulator of energy homeostasis and fat metabolism.
They theorized that when AMPK is chronically activated, it becomes less sensitive to imbalances in energy demand and nutrient supply. When metabolic imbalances run unchecked, they alter lipid metabolism, which explains how apolipoprotein E accumulates as deposits near the RPE layer.
Testing that theory, the researchers chemically inhibited the chronically activated AMPK in the patient-derived RPE model and found fewer deposits of apolipoprotein E, and less abnormal secretion of vascular endothelial growth factor.
Next, using the patient-derived RPE model, they tested two potential treatment strategies: A gene therapy approach to encourage expression of normal CTRP5 in the RPE model, and the use of the diabetes drug metformin, which appears to modulate AMPK activity, re-sensitizing it to changes in cellular energy status. Both strategies prevented signs of L-ORD in RPE models.
“Importantly, we now have two potential strategies to disrupt the L-ORD disease process. While gene therapy may be years away, metformin is a drug that’s long been used to treat diabetes,” said Bharti, who with NEI collaborators is planning a clinical trial to test the drug in people with L-ORD.
Although L-ORD disease is rare, it shares similarities with other retinal degenerations like age-related macular degeneration, a leading cause of vision loss. The model developed for this study may prove helpful in understanding such age-related disease changes in the RPE.
The study was funded by the NEI Intramural Research Program grants EY005121 and EY026525.
This press release describes a basic research finding. Basic research increases our understanding of human behavior and biology, which is foundational to advancing new and better ways to prevent, diagnose, and treat disease. Science is an unpredictable and incremental process— each research advance builds on past discoveries, often in unexpected ways. Most clinical advances would not be possible without the knowledge of fundamental basic research. To learn more about basic research, visit https://www.nih.gov/news-events/basic-research-digital-media-kit.
NEI leads the federal government’s research on the visual system and eye diseases. NEI supports basic and clinical science programs to develop sight-saving treatments and address special needs of people with vision loss. For more information, visit https://www.nei.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
These tax loss stocks always have a point where the price gets hit so low, that the turn comes and takes people by surprise.
Buying these oversold stocks, and selling in January, has worked many times for me in the past.
And if there is news in early January, I have held on for some great runs going into Spring.
Looks like the iBox has been updated. Great data on the many "unmet needs" in the vision market. Huge $$$ numbers....and no real cures or effective long treatments.
Nice summary of the Scientific Advisory Board members too.
Tax loss selling will be over soon.....
Correct, trader.
The weakness here is because of tax loss selling. Too tempting a sale for those who bought much higher.
Simple supply and demand.
More selling and no new interest for new buying ..yet.
No surprise. Self fulfilling. No momentum. Low volume. No news. Nothing to attract more buying to sop up the tax loss selling
If you think news is coming, you buy or, hold
If you have no confidence, and could use a tax loss, you sell.
Happy Holidays
How UNQL performs after uplisting will be helpful info for another stock I own.
I ignored the noise here and bought UNQL at .0166
If you think retail investors can short an unmargineable stock, you leave me speechless.
So far, so good. Pretty happy right now.
OCGN Short Interest
https://www.nasdaq.com/market-activity/stocks/ocgn/short-interest
Do you understand tax loss selling?
This company has been very quiet recently. If you bought in at .12 or better, selling can shelter a lot of capital gains.
Those selling have to wait 31
Days to keep the loss. There is a risk that CUBT could be much higher on news.
Everyone has to decide for their situation.
But if there is good news, these sellers can become re-buyers. And new buyers coming in can really flip this trend to up quickly .
One thing for sure. No insiders can sell.
Two more weeks of tax selling
Thanks for the link. It is obvious that the NEI/NHI are pursuing treatments for vision loss. An aging population that have failing eyesight is very costly to Medicare and Medicaid.
If you can slow the progression of vision loss, the US can potentially save billions annually. Which is why the govt is funding promising treatments.
In the meantime, book your loss. Or average down . In 30 days, the sellers will have a lower tax bill.
The buyers will probably have nice unrecognized and yet to be taxed capital gains.
Does not look like tax loss selling will end until the end of the month. The update certainly did not help
Most of the biotechs are getting clobbered because they had such a great run early in the year. Now the tax loss selling is hitting them.
Some of these names will do really well in January with any good news and selling largely over.
Hard to call the bottom in December,though.
JMO
Up listing at the same time as the RS is the right way to do this.
Stocktwits had a post that saw a Linked In post Mid Atlantic Therapeutics
FWIW
-----
$CUBT
Their partner, Mid-Atlantic Therapeutics, had a post on Linked IN about vaccines.
linkedin.com/posts/david-ho...
Trying to connect the dots. CUBT has someone on board with a background and connections in the vaccine arena.
Dr. Sohn to Oversee Development of Next Gen COVID-19 Vaccine to Treat Kidney Failure Patients, Late-Stage Rabies Therapeutic and Age-related Macular Degeneration
"Dr. Sohn started the U.S. Vaccine Business for SmithKline Beecham and led the launch of its first vaccine in the U.S. and helped shape their global vaccine portfolio pipeline as a member of the International Vaccine Steering Committee. Subsequently, she led the US commercialization of the company’s largest CNS product. Dr. Sohn later became senior vice president, Worldwide Business Development and a member of the global executive committee at GlaxoSmithKline Consumer Healthcare where she led U.S. and global transactions."
finance.yahoo.com/news/cura...
David Horn, MD on LinkedIn: Could even better Covid-19 vaccines be coming soon?
via: Li
TSLA will not be the only innovative EV option
Marrone Bio's Next-Generation Product for Environmentally Sustainable Pest Control Demonstrates Substantial Yield Gains in 2021 Field Trials
Estimated peak potential revenue for MBI-306 and its variants is $100 million
DAVIS, Calif., Dec. 08, 2021 — Field trials in 2021 for Marrone Bio Innovations’ (NASDAQ: MBII) next-generation product for environmentally sustainable control of yield-robbing pests in corn and soybeans demonstrated excellent efficacy with substantial yield gains at reduced application rates.
“MBI-306 continues to demonstrate the benefits that farmers and consumers desire in healthier foods grown with a lighter environmental footprint,” said Marrone Bio’s Chief Executive Officer Kevin Helash. “This second-generation product offers growers a more sustainable solution to controlling pests with better yields. Additionally, with a reduced application rate, MBI-306 will be even more competitive against leading synthetic standards in terms of efficacy, price and ease of use.” Helash added, “We anticipate MBI-306 and its variants will generate a peak potential revenue of $100 million, providing valuable return to our stakeholders as well.”
MBI-306 will offer corn growers a new alternative in treating for corn rootworm, a pest that accounts for more than $1 billion of crop damage annually1. When tested as a seed treatment to control corn rootworm larvae, MBI-306 improved corn yields by up to 23 bushels per acre, a 14% increase when compared with untreated seed. This bioinsecticide also outperformed the leading commercial standard, delivering a 4% yield advantage. These yield gains equate to an estimated return on investment of $131 per acre versus untreated seed and $41 per acre versus current commercial products.
Similar benefits were demonstrated against soybean cyst nematode, the leading pest in soybeans and contributor to more than $1 billion in crop damage2. As a seed treatment, MBI-306 increased soybean yields by 11 bushels an acre, a 19% improvement and $130 per acre in additional revenue versus untreated seed. This novel bionematicide also showed excellent control with 6% higher yields when compared with commonly used treatments, providing growers an additional $47 per acre in returns.
Marrone Bio is an international leader in sustainable bioprotection and plant health solutions, with 18 commercial products and 15 products in its research and development pipeline, including MBI-306. MBI-306 is a second-generation novel bioinsecticide/bionematicide built on the same proprietary microbe that serves as the active ingredient in the company’s Venerate® XC Bioinsecticide and Majestene® Bionematicide.
MBI-306 was recently submitted to the U.S. Environmental Protection Agency for approval and is anticipated to be commercially available for the 2023/2024 growing season. It has shown to be non-toxic to humans, wildlife, aquatic life, earthworms and pollinators.
MBI-306 also was tested in 2021 as a soil treatment, or in-furrow, for control of corn rootworm larvae, with an average yield advantage of more than 21 bushels per acre versus no treatment. Additional data on this and other 2021 field trial results can be found on the company’s blog https://marronebio.com/news/bio-bites/.
Sources
Utah State University Extension
University of Minnesota Extension
About Marrone Bio Innovations
Marrone Bio Innovations Inc. (NASDAQ: MBII) is a growth-oriented agricultural company leading the movement to environmentally sustainable farming practices through the discovery, development and sale of innovative biological products for crop protection, crop health and crop nutrition. Our portfolio of 18 products helps customers operate more sustainably while increasing their return on investment. The company’s commercial products are sold globally and supported by a robust portfolio of more than 500 issued and pending patents. Our end markets include row crops; fruits and vegetables; trees, nuts and vines; and greenhouse production. Marrone Bio’s research and development program uses proprietary technologies to isolate and screen naturally occurring microorganisms and plant extracts to create new, environmentally sound solutions in agriculture.
Learn more about Marrone Bio Innovations at www.marronebio.com. We also use our investor relations website, https://investors.marronebio.com, as well as our corporate Twitter account, @Marronebio, as means of disclosing material non-public information, and encourage our investors and others to monitor and review the information we make public in these locations. Follow us on social media: Twitter, LinkedIn and Instagram.
Been doing a bit more DD.
Trying to justify my now large position in CUBT. This info is pretty much overlooked by investors and traders. I get it --the stock has been weak from the motivated sellers taking a tax loss. But this vaccine potential with IMT 504 from Mid-Atlantic Thereapeutics is, imo, pretty significant for both MABT and CUBT. The video below was from BEFORE CUBT signing an agreeement with MABT on IMT504 as an adjuvant for vaccines. Obviously they mentioned COVID 19...but the potential goes beyond that. It looks like they see IMT504 as improving the antibody titer response for ANY vaccine.
There is an great slide at the 18 minute point talking about the various COVID 19 vaccines and how much better the antibody response when adding IMT504 to the vaccination. A 4X increase in antibody response over the Moderna vaccine alone (without IMT 504) should be getting more attention, imo.
Looking good here. Breakout highs. Insiders buying.
EV sales ramping up next year.
Life is good.
Been thinking the same thing, before the end of the year
NEI is doing trials on ORAL Metformin with Stargardt's disease.
https://clinicalstudies.info.nih.gov/ProtocolDetails.aspx?id=2020-EI-0163
It would make sense if they are researching the oral, that the eye drop delivery would be studied too. And CUBT would have the inside track on that.
Has anyone called the company recently? I got the e-mail from Investor Relations yesterday, but it was after the close.
Stocktwits lit up today. Hope we see some news, blog, articles mentioned on metformin eye drops as mentioned earlier.
BTW, my friends still have not bought in. FWIW.
Would like to see 3 million shares and a close at the high of the day
CUBT chart is turning up, bb. Up nicely from its recent lows from tax loss selling.
Slow and steady recovery is preferable, imo, to a huge volume price spike. Building volume and giving time to those investors who want to accumulate by buying from weaker (tax loss sellers) hands would be setting up for a higher base to move when the Company comes out with news/PR.
Again, JMO.
Company Announces Addition of Dr. Kapil Bharti and Dr. Dimiter Dimitrov to Scientific and Clinical Advisory Board
Boca Raton, FL / PRNewswire / April 29, 2021 / Curative Biotechnology, Inc. (OTC: CUBT) a development stage biomedical company focused on novel therapies for rare diseases, announced today the Company’s trading symbol change from “CTYX” to “CUBT”. As previously announced, the Company had changed its corporate name to Curative Biotechnology, Inc. to better represent its mission to discover and develop therapeutics for patients who have few, if any, effective treatments for rare diseases. Curative Biotechnology Inc. Chairman and President Paul Michaels said, “This name and symbol change are reflective of our total remaking of this company and our mission to create treatments or cures for unmet medical needs for patients around the world.”
Michaels added, “We are also very pleased to announce two additions to our Scientific and Clinical Advisory Board. Both are important thought leaders in their respective fields and have joined our Scientific and Clinical Advisory Board to help guide our programs through pre-clinical and clinical development.”
Dr. Kapil Bharti
Kapil Bharti, Ph.D. from the National Eye Institute (NEI) at the National Institutes of Health (NIH) has joined our Scientific and Clinical Advisory Board. Dr. Bharti is the lead inventor on the U.S. and Worldwide patent applications licensed exclusively to Curative Biotech to repurpose Metformin into an eye drop to treat degenerative eye diseases like macular degeneration, diabetic retinopathy, Stargardt’s disease, and others.
He is a world leader in his field, and we look forward to working closely with him as we prepare to move into clinical trials. Dr. Bharti earned his Ph.D. from J.W. Goethe University, Frankfurt, Germany, graduating summa cum laude. He did his postdoc work at NIH, where he published numerous papers on pigment cell biology, transcription regulation and the developmental biology of the eye.
Dr. Bharti has won a number of awards including being the first Earl Stadtman Tenure Track Investigator at NEI, NIH Directors award and NEI Directors Dr. Karl Kupfer Visionary award for his groundbreaking research on developing ocular celltherapies.
NIH study traces molecular link from gene to late-onset retinal degeneration
Scientists have discovered that gene therapy and the diabetes drug metformin may be potential treatments for late-onset retinal degeneration (L-ORD), a rare, blinding eye disease. Researchers from the National Eye Institute (NEI), part of the National Institutes of Health generated a “disease-in-a-dish” model to study the disease. The findings are published in Communications Biology.
“This new model of a rare eye disease is a terrific example of translational research, where collaboration among clinical and laboratory researchers advances knowledge not by small steps, but by leaps and bounds,” said Michael F. Chiang, M.D., director of the NEI, part of the National Institutes of Health.
L-ORD is a rare, dominantly inherited disorder, meaning that it can occur when there is an abnormal gene from one parent. L-ORD is caused by a mutation in the gene that encodes the protein CTRP5. People with the disorder develop abnormal blood vessel growth and deposits of apolipoprotein E, which is involved in fat metabolism within the retina. Symptoms, including difficulty seeing in the dark and loss of central vision, usually appear around age 50 to 60. As L-ORD progresses, cells in the retinal pigment epithelium (RPE), a layer of tissue that nourishes the retina’s light-sensing photoreceptors, shrink and die. Loss of RPE leads to the loss of photoreceptors and in turn, to loss of vision.
The investigators were led by Kapil Bharti, Ph.D., who directs the NEI Ocular and Stem Cell Translational Research Section, and Kiyoharu (Josh) Miyagishima, Ph.D. and Ruchi Sharma, Ph.D., staff scientists in the section and leading authors of the study. They developed a laboratory model that uses induced pluripotent stem cells developed from skin (fibroblasts) to make RPE. They generated RPE from two siblings with L-ORD and, for comparison, RPE from two of the patients’ unaffected siblings who lacked the disease-causing mutation.
The patient-derived RPE shared key characteristics of the disorder in humans, including deposits of apolipoprotein E near the tissue, and abnormal secretions of vascular endothelial growth factor, a protein that stimulates blood vessel growth. The RPE cells also were dysmorphic, or deformed. By contrast, RPE from the unaffected siblings appeared normal. The researchers also found that the patient-derived RPE secreted far less of the mutant and the non-mutant CTRP5 protein compared with the models made from the unaffected siblings.
Using a computer modeling technique, they showed that mutant CTRP5 was less likely to bind with cell receptors that help fine-tune fat metabolic regulation. Less receptor binding in turn leads to chronic activation of AMP-activated protein kinase (AMPK), a key regulator of energy homeostasis and fat metabolism.
They theorized that when AMPK is chronically activated, it becomes less sensitive to imbalances in energy demand and nutrient supply. When metabolic imbalances run unchecked, they alter lipid metabolism, which explains how apolipoprotein E accumulates as deposits near the RPE layer.
Testing that theory, the researchers chemically inhibited the chronically activated AMPK in the patient-derived RPE model and found fewer deposits of apolipoprotein E, and less abnormal secretion of vascular endothelial growth factor.
Next, using the patient-derived RPE model, they tested two potential treatment strategies: A gene therapy approach to encourage expression of normal CTRP5 in the RPE model, and the use of the diabetes drug metformin, which appears to modulate AMPK activity, re-sensitizing it to changes in cellular energy status. Both strategies prevented signs of L-ORD in RPE models.
“Importantly, we now have two potential strategies to disrupt the L-ORD disease process. While gene therapy may be years away, metformin is a drug that’s long been used to treat diabetes,” said Bharti, who with NEI collaborators is planning a clinical trial to test the drug in people with L-ORD.
Although L-ORD disease is rare, it shares similarities with other retinal degenerations like age-related macular degeneration, a leading cause of vision loss. The model developed for this study may prove helpful in understanding such age-related disease changes in the RPE.
The study was funded by the NEI Intramural Research Program grants EY005121 and EY026525.
This press release describes a basic research finding. Basic research increases our understanding of human behavior and biology, which is foundational to advancing new and better ways to prevent, diagnose, and treat disease. Science is an unpredictable and incremental process— each research advance builds on past discoveries, often in unexpected ways. Most clinical advances would not be possible without the knowledge of fundamental basic research. To learn more about basic research, visit https://www.nih.gov/news-events/basic-research-digital-media-kit.
NEI leads the federal government’s research on the visual system and eye diseases. NEI supports basic and clinical science programs to develop sight-saving treatments and address special needs of people with vision loss. For more information, visit https://www.nei.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
Tax loss selling crushed this one. Which means it might be a good one for a January bounce. imo
Saw this on StockTwits today.
The investigators were led by Kapil Bharti, Ph.D., who directs the NEI Ocular and Stem Cell Translational Research Section, and Kiyoharu (Josh) Miyagishima, Ph.D. and Ruchi Sharma, Ph.D., staff scientists in the section and leading authors of the study.
Next, using the patient-derived RPE model, they tested two potential treatment strategies: A gene therapy approach to encourage expression of normal CTRP5 in the RPE model, and the use of the diabetes drug metformin, which appears to modulate AMPK activity, re-sensitizing it to changes in cellular energy status. Both strategies prevented signs of L-ORD in RPE models.
“Importantly, we now have two potential strategies to disrupt the L-ORD disease process. While gene therapy may be years away, metformin is a drug that’s long been used to treat diabetes,” said Bharti, who with NEI collaborators is planning a clinical trial to test the drug in people with L-ORD.
https://www.nih.gov/news-events/news-releases/nih-study-traces-molecular-link-gene-late-onset-retinal-degeneration#.YbI3HelYrvs.linkedin
I think NEI stands for the National Eye Institute which is part of the NIH.
His point that "While gene therapy may be years away, metformin is a drug that’s long been used to treat diabetes" suggests to me that they do not think metformin therapy will take long to prove out in trials.
JMO
Pretty detailed delivery schedule. Wonder if they have run into problems with Bitmain keeping up with all the demand.
Biotechs are starting to move up again
Catch that bottom.
Another week of this backing and filling and we may have seen the bottom. Five friends of mine gave heard me talk of CUBT this year and never bought in. Down here? Now they are ready.
Figures they will get in at a better price than my average.
Three want to see a high volume close above .07 before getting in.
Fwiw